World Journal of
Pharmaceutical and Life Sciences

IN-VITRO EVALUATION OF CELL VIABILITY STUDIES OF TRANSITIONAL CELL CARCINOMA USING SIMILAR MOLECULE – NIVOLUMAB

Raheem Unnisa Shaik*, Dr. Syed Ahmed Hussain, Maimuna Fatima, Umaima Batool Osmani, Arshiya Tarannum, Faheem Unnisa and Nazneen

ABSTRACT

Aim: This study aims to evaluate the efficacy of Nivolumab, an immune checkpoint inhibitor, in reducing cell viability in kidney cancer cell lines compared to the marketed drug Pembrolizumab, used for treating Non-Small Cell Lung Cancer (NSCLC). Objective: The objective is to investigate the cytotoxic effects of Nivolumab through various cell viability assays, highlighting its potential as a therapeutic option for NSCLC. Research: Nivolumab and Pembrolizumab were tested on kidney cancer cell lines using MTT, CellTiter-Glo, Alamar Blue, SRB, and LDH assays. Results showed a significant decrease in cell viability with increasing concentrations of Nivolumab across all assays, indicating its cytotoxic effects. Conclusion: Nivolumab demonstrates significant anti-cancer activity in kidney cancer cell lines, supporting its potential as an effective treatment for NSCLC. These findings warrant further exploration in clinical settings to enhance therapeutic outcomes for NSCLC patients.

[Full Text Article]   [Download Certificate]